Introduction
T lymphocytes expressing a chimeric antigen receptor (CAR) can be adoptively transferred to target a range of human malignancies, including non-Hodgkin's and Hodgkin's lymphomas. [1] [2] [3] [4] [5] CARs most commonly combine the antigen-binding specificity of a monoclonal antibody with the effector endodomain of the CD3/T-cell receptor complex (z-chain), and redirect the specificity of T lymphocytes toward surface antigens expressed by tumor cells. 6 CARs that target B-lineage-restricted antigens such as CD19, 7,8 CD20 9 and the light chain of human immunoglubulins, 10 or CD30 expressed by Reed-Sternberg cells, 2, 4 have been cloned and validated in preclinical lymphoma/leukemia models, and some are currently in phase I clinical trials. 1, 3, 5, 11 However, it is evident from both clinical trials 1, 12, 13 and preclinical models 3, 10, 14 that the expansion and persistence of CAR-modified T cells in vivo are hampered by the lack of costimulatory signals after engagement with target antigens, as many tumor cells downregulate their expression of the costimulatory molecules required for optimal and sustained T-cell function, proliferation and persistence. 3, 5 This limitation has been partially resolved by the construction of 'second-generation' CARs in which a costimulatory endodomain derived from molecules such as CD28 10, 14, 15 or 4-1BB 16, 17 have been incorporated within the chimeric receptors. T cells expressing these enhanced CARs retain their cytotoxic function, but, upon antigen engagement, they produce interleukin-2 (IL-2) that helps to sustain their activation and expansion, 10, 14, 15 and augments antitumor activity. 3, 10, 14 To further potentiate the costimulation of CAR-modified T cells, 'third-generation' CARs have been developed that contain multiple costimulatory endodomains such as combinations of CD28 and 4-1BB [18] [19] [20] [21] or CD28 and OX40, 22 which may have superior activity compared with those encoding single costimulatory endodomains. [18] [19] [20] 22 We now describe an alternative strategy. We have engineered CAR-modified T cells to receive not only costimulation through the CD28 pathway but also to ectopically produce IL-15, a cytokine crucial for T-cell homeostasis and survival. 23, 24 As these changes may increase the risk of direct toxicity and uncontrolled proliferation, 25 we have also included a suicide gene that can be pharmacologically activated to eliminate transgenic cells as required. 26, 27 Materials and methods
Cell lines
The following cell lines were used: Daudi and Raji (CD19 þ Burkitt lymphoma cell lines), HDLM-2 (CD30 þ CD19 À Hodgkin's lymphoma cell line), Karpas-299 (CD30 þ CD19 À anaplastic lymphoma cell line) and K562 (chronic erythroid leukemia cell line). All cells were purchased from American Type Culture Collection and maintained in culture in RPMI-1640 (Gibco-BRL, San Francisco, CA, USA) supplemented with 10% fetal bovine serum (Hyclone, Waltham, MA, USA) and 2 mM L-glutamine (Gibco-BRL).
Plasmid construction and retrovirus production
The cassette encoding the single-chain antibody targeting CD19, 28 the CD28 endodomain 10 and the z-chain of the T-cell receptor complex 10 was cloned into the SFG retroviral backbone to generate the CAR.19 retroviral vector (Supplementary Figure 1A) . We then generated a second retroviral vector encoding the same CD19-specific CAR in combination with the human IL-15 gene 27 and the inducible caspase-9 suicide gene that induces apoptosis upon specific binding with the small molecule dimerizer Chemical inducer of dimerization (CID) AP20187. 26 The three genes were linked together using 2A sequence peptides derived from foot-and-mouth disease virus, 27 and cloned into the SFG retroviral vector to generate the CAR coexpressed with IL-15 and the inducible suicide gene caspase-9 (iC9/CAR.19/IL-15) retroviral vector ( Supplementary Figure 1) . The vectors encoding FireFly luciferase (FFLuc) and the fusion protein, enhanced green florescent protein-FFLuc (eGFP-FFLuc), used for in vivo imaging have been described previously. 4, 10 Transient retroviral supernatants were produced as previously described. 10 
Generation of CAR-modified T cells
Peripheral blood mononuclear cells were obtained from four healthy donors and three patients with chronic lymphocytic leukemia (B-CLL) according to the approved protocols of the local institutional review board. Peripheral blood mononuclear cells or CD3 þ -enriched T cells (Miltenyi, Bergisch Gladbach, Germany) for samples collected from B-CLL patients 10 were activated with OKT3 (Ortho Biotech, Bridgewater, NJ, USA) and CD28 (Becton Dickinson, Mountain View, CA, USA) antibodies and recombinant human IL-2 (100 U/ml) (Proleukin; Chiron, Emeryville, CA, USA) in complete media (RPMI-1640 (Gibco-BRL) 45%, Click medium (Irvine Scientific, Santa Ana, CA, USA) 45%, supplemented with 10% fetal calf serum (Hyclone) and 2 mM L-glutamine (GIBCO-BRL)). 10 Activated T cells were transduced with retroviral supernatants on day 3 in plates coated with recombinant fibronectin fragment (FN CH-296; Retronectin; Takara Shuzo, Otsu, Japan). 10 After transduction, T cells were expanded using IL-2 and then used for the experiments described below.
Coculture experiments Cytokine production. At 7 days after transduction, control non-transduced (NT), CAR.19 þ and iC9/CAR.19/IL-15 þ T cells (1 Â 10 6 cells per well) were cocultured in 24-well plates with B-CLL cells (enriched-CD19 þ cells) in an effector and tumor cell ratio (E:T) of 1:1. Culture supernatants were collected after 24, 48 and 72 h of culture to measure the production of IL-2, IL-15 and interferon-g using specific enzyme-linked immunosorbent assays (R&D Systems, Inc., Minneapolis, MN, USA).
T-cell expansion. To evaluate the T-cell growth, control NT, CAR.19 þ and iC9/CAR.19/IL-15 þ T cells were maintained in culture and stimulated once a week with CD19 þ B-CLL cells (E:T ratio of 1:2) without any addition of exogenous cytokines. Cells were cultured for 5 weeks, and counted by Trypan blue exclusion every week.
T-cell division and death. To measure the cell division of T cells upon antigen stimulation, we labeled control NT, CAR.19 þ and iC9/CAR.19/IL-15 þ T cells with carboxyfluorescein diacetate succinimidyl ester (CFSE; eBioscience, Inc., San Diego, CA, USA). 29 We then stimulated the T cells with CD19 þ B-CLL cells (E:T ratio of 2:1) and measured the CFSE dilution by fluorescence-activated cell sorting (FACS) analysis after 5 days of culture. To measure T-cell death upon antigen stimulation, we used the Annexin-V/7-amino-actinomycin (7-AAD) staining and FACS analysis. 27 Antitumor effects. To evaluate elimination of tumor cells, control NT, CAR.19 þ and iC9/CAR.19/IL-15 þ T cells were cocultured with Daudi cells (CD19 þ ) (E:T ratio of 5:1). After 3 days of culture, cells were collected and residual tumor cells were enumerated by FACS analysis. For samples obtained from B-CLL patients, antitumor effects were evaluated against autologous B-CLL cells (E:T ratio of 2:1). In these experiments, B-CLL cells were labeled with CFSE and enumerated by FACS after 3 to 4 days of coculture. 10 In some experiments, we used wild-type Karpas cells (CD30 þ CD19 À ) or CD19 þ transgenic Karpas as the targets.
Activation of the suicide gene. CID AP20187 (ARIAD Pharmaceuticals, Cambridge, MA, USA) was kindly provided by Dr Spencer (Baylor College of Medicine) and added at the indicated concentrations to T-cell cultures. The elimination of transgenic cells coexpressing the inducible suicide gene was evaluated 24-48 h after incubation using Annexin-V/7-AAD staining and FACS analysis. 27 Immunophenotyping Cells were stained with fluorescein isothiocyanate-, phycoerythrin-or peridinin-chlorophyll-protein-conjugated monoclonal antibodies. To stain the tumor cells, we used CD19, CD20 and CD30 from Becton Dickinson (Mountain View, CA, USA). For the T lymphocytes, we used CD3, CD4, CD8, CD56, CD45RA, CD45RO, CD62L, CD27, CD28, CCR7, Bcl-2 and programmed death 1 (PD-1) from Becton Dickinson. To detect the expression of CAR.19, we used a monoclonal antibody Fc-specific cyanine-Cy5-conjugated provided by Jackson ImmunoResearch (West Grove, PA, USA), which recognized the IgG1-CH 2 CH 3 component of the artificial receptor. 10 Apoptosis was measured using Annexin-V and 7-AAD staining (Becton Dickinson). Cells were analyzed by FACScan (Becton Dickinson), equipped with the filter set for triple fluorescence signals.
Chromium release assay
We used 4-h 51 Cr-release assays to evaluate the cytotoxic activity of control and CAR þ T lymphocytes. 10 The labeled targets tested included Daudi (CD19 þ target), HDLM-2 (CD19target) and K562 (natural killer cell target).
Xenogeneic lymphoma models
To assess the persistence and antitumor effect of CAR þ T cells in vivo, we used a severe combined immunodeficient (SCID)-lymphoma human xenograft model. Mouse experiments were performed in accordance with the Baylor College of medicine animal husbandry guidelines according to the approved protocol of the institutional animal care and use committee.
Trafficking and expansion of CAR þ cells. In the first set of experiments to evaluate engraftment, Daudi and Raji cells were labeled with FFLuc. SCID mice (8-10-week old; Harlan Sprague Dawley Inc., Indianapolis, IN, USA) were sublethally irradiated (250 rad) and injected intravenously (i.v.) with either Daudi (3 Â 10 6 ) or Raji (2 Â 10 5 ) cells. Tumor engraftment was measured using the in vivo imaging system as previously described. 4, 10, 27 In brief, mice were injected intraperitoneally (i.p.) with D-luciferin (150 mg/kg), and analyzed using the Xenogen-IVIS Imaging System (Caliper Life Sciences, Hopkinton, MA, USA). Signal intensity was measured as total photon/sec/cm 2 /sr (p/s/cm 2 /sr) as previously described. 27, 29, 30 In the second set of experiments to evaluate the in vivo trafficking and persistence of CAR þ cells, either control or CAR.19 þ or iC9/CAR.19/IL-15 þ cells were labeled with eGFP-FFLuc gene. 4, 27 At 7 days after engraftment with unlabeled Daudi or Raji cells, mice received i.v. 10 Â 10 6 T cells. No exogenous cytokines were administered to the mice. Trafficking, persistence and expansion of labeled T cells were measured using the Xenogen-IVIS Imaging System. 4, 10, 27 Antitumor effect of CAR þ T cells. To measure the antitumor effects of CAR þ T cells, mice were engrafted either i.p. or subcutaneously with Daudi cells (1 Â 10 6 cells) labeled with the FFLuc gene. After 10 days, when the tumor was consistently measurable by light emission, mice received either control NT or CAR.19 þ or iC9/CAR.19/IL-15 þ T cells (10 Â 10 6 ; 2 doses, 1 week apart). For these experiments we used unlabeled T cells. We evaluated tumor growth using the Xenogen-IVIS Imaging System. 4, 10, 27 In vivo validation of the suicide gene. To evaluate the functionality of the suicide gene, mice bearing tumor cells and receiving iC9/CAR.19/IL-15 þ T cells labeled with the eGFP-FFluc gene were treated with CID (50 mg) i.p. 2 to 3 doses every other day. 27 CID treatment was initiated when the T-cell bioluminescent signal was exponentially increasing, indicating active expansion of the transgenic cells. Mice were then imaged as described above.
Statistical analysis
Student's t-test was used to determine the statistical significance of differences between samples, and Po0.05 was accepted as indicating a significant difference. For the bioluminescence experiments, intensity signals were summarized using mean±s.d. at baseline and multiple subsequent time points for each group of mice. Changes in intensity of signal from baseline at each time point were calculated and compared using the Wilcoxon signed-ranks test. 27, 29 Results T lymphocytes transduced with iC9/CAR. 19/IL-15 vector release IL-15 after antigen stimulation and have greater expansion than T cells transduced with the CAR.19 vector Activated T lymphocytes were equally transduced with one of two retroviral vectors encoding either CAR.19 or iC9/CAR.19/ IL-15 ( Supplementary Figure 1 ). We then measured IL-15 production by iC9/CAR.19/IL-15 þ T cells and determined whether production was antigen dependent. Control NT, CAR.19 þ and iC9/CAR.19/IL-15 þ T lymphocytes were cultured with or without CD19 þ target cells (B-CLL). 10 Culture supernatants were collected at multiple time points to measure IL-15 release. As shown in Figure 1a , IL-15 was undetectable in supernatants collected from stimulated or unstimulated control NT and CAR.19 þ T cells. In contrast, iC9/CAR.19/IL-15 þ T cells produced small amounts of IL-15 in the absence of antigen stimulation (25 pg/ml/10 6 cells (range 3-47 pg/ml)), which significantly increased 72 h after antigen stimulation (240 pg/ml/10 6 cells (range 110-380 pg/ml); Po0.001). Importantly, when iC9/CAR.19/IL-15 þ T cells were maintained in culture for more than 4 weeks by weekly stimulation with CD19 þ B-CLL cells, we found that the production of IL-15 was sustained upon each antigen stimulation ( Figure 1b ). As CAR.19 contains the costimulatory endodomain CD28, we also measured IL-2 production by genetically modified T cells. 10, 14, 15 As shown in Figure 1c , incorporation of IL-15 within the iC9/CAR.19/IL-15 vector did not compromise the production of IL-2 by iC9/CAR.19/IL-15 þ T cells after antigen stimulation (mean 1527 pg/ml/10 6 cells, range 740-2000 for CAR.CD19 þ cells and mean 1643 pg/ml/10 6 cells, range 631-2000 for iC9/CAR.19/IL-15 þ T cells; P ¼ 0.8).
To evaluate whether IL-15 and IL-2 production by iC9/CAR. 19 
Transgenic expression of IL-15 enhances the survival of CAR-modified T cells
To distinguish whether the greater number of iC9/CAR.19/ IL-15 þ T cells compared with CAR.19 þ T cells after antigen stimulation was due to increased proliferation or reduced cell death, we analyzed the proliferation and apoptosis of T cells upon antigen stimulation, using CFSE-and Annexin-V/7-AADbased assays, respectively. To measure cell division, T cells were labeled with CFSE and then stimulated with CD19 þ B-CLL cells. As shown in Figure 2a , after 5 days of culture, CFSE dilution was comparable for CAR.CD19 þ and iC9/CAR.19/ IL-15 þ T cells (77 ± 20 and 65 ± 20%, respectively, P ¼ 0.07), suggesting similar rates of cell division. In contrast, the death rate of iC9/CAR.19/IL-15 þ T cells was reduced 5 days after antigenic stimulation, as assessed by Annexin-V/7-AAD staining (annexin-V þ /7-AAD þ cells were 32 ± 19 and 10 ± 6% for CAR.19 þ and iC9/CAR.19/IL-15 þ T cells, respectively, Po0.001; Figure 2b ). The improved viability of transgenic cells producing IL-15 also correlated with an increased expression of antiapoptotic genes, such as Bcl-2 ( Figure 2c ).
iC9/CAR.19/IL-15 þ T lymphocytes have enhanced expansion in vivo
To evaluate the trafficking and persistence of our modified T cells in vivo, we used a SCID mouse lymphoma xenograft, and an extensively validated bioluminescence imaging system. 4, 27, 29 We began by evaluating the tumor engraftment after i.v. inoculation of either Daudi and Raji, both of which are CD19 þ lymphoma cell lines, labeled with FFLuc. We found that 5 days after infusion, Daudi (3 Â 10 6 cells) had engrafted diffusely in bone marrow, lymphnodes and spleen (Figure 3a (Figures 3a and d) .
T-cell bioluminescence remained barely detectable when Daudi-or Raji-engrafted tumor cells were treated with labeled control NT T cells (data not shown). Importantly, although the bioluminescence signal corresponding to CAR.19 þ T cells only modestly increased by day 25 after infusion (from 4 Â 10 5 ±8 Â 10 3 to 4 Â 10 5 ±4 Â 10 4 for mice engrafted with Daudi, and from 1 Â 10 5 ± 2 Â 10 4 to 1.2 Â 10 5 ± 3 Â 10 4 for mice engrafted with Raji), corresponding to 1.1-and 1-fold increase, respectively (Figures 3c and f) , the signal from iC9/CAR.19/IL-15 þ T cells significantly increased over the following 25 days (from 5 Â 10 5 ± 8 Â 10 4 to 9 Â 10 6 ± 3 Â 10 6 for mice engrafted with Daudi and from 5 Â 10 5 ±8 Â 10 4 to 2 Â 10 6 ± 1 Â 10 6 for mice engrafted with Raji), corresponding to 15-and 3-fold increase, respectively (P ¼ 0.02 and P ¼ 0.01; Figures 3c and f) , showing increased expansion and persistence of these cells.
T lymphocytes transduced with the iC9/CAR.19/IL-15 vector have enhanced antitumor activity
We measured the cytotoxic activity of T cells against CD19 þ and CD19tumor cell lines using standard 51 Cr-release assays. (Figure 4a ). Control T cells showed no significant cytotoxic activity against any of these target cell lines. In parallel, both CAR.19 þ and iC9/CAR.19/IL-15 þ T cells produced equal amounts of interferon-g in response to CD19 þ tumor cells (mean of 8327 pg/ml/10 6 cells, range 5080-12 510 for CAR.CD19 þ cells and of 9147 pg/ml/10 6 cells, range 3025-18 010 for iC9/CAR.19/IL-15 þ cells; Figure 4b ). To further confirm that IL-15 production by iC9/CAR.19/IL-15 þ T cells enhanced the elimination of tumor cells through the CAR, we cocultured T cells with wild-type Karpas-299 tumor cells (CD30 þ CD19 À ), or with Karpas cells modified to stably express the CD19 molecule (Karpas CD30 þ CD19 þ ). After 4 to 5 days in an initial T cell and tumor cell ratio of 5:1, residual tumor cells were quantified by FACS analysis enumerating CD30 þ tumor cells. Both CAR.19 þ and iC9/CAR.19/IL-15 þ T cells efficiently eliminated Karpas CD19 þ tumor cells when T-cell antitumor activity was evaluated using T-cell lines maintained in short-term culture (1 week) after transduction (data not shown).
In contrast, when T-cell lines were maintained in culture for 4 weeks, and stimulated weekly with CD19 þ B-CLL cells, only iC9/CAR.19/IL-15 þ T cells maintained their ability to completely eliminate tumor cells from the culture (residual tumor cells 1 ± 0.7 and 10 ± 5% for iC9/CAR.19/IL-15 þ T cells and CAR.19 þ T cells, respectively; P ¼ 0.001). Importantly, even after 4 weeks of expansion in culture, the antitumor effects of both CAR.19 þ and iC9/CAR.19/IL-15 þ T cells remained antigen specific, as they lacked activity against wild-type (CD19 À ) Karpas-299 cells (Figure 4c ). To discover potential mechanisms for the sustained effector function of IL-15-producing cells upon prolonged culture and repeated antigen stimulation, we evaluated the expression of PD-1, a marker of T-cell exhaustion, 31 and found that iC9/CAR.19/IL-15 þ T cells had lower expression of PD-1 (PD-1 þ T cells o15%) 2 days after stimulation with B-CLL cells than CAR.19 þ T cells (PD-1 þ T cells 440%; Figure 4d ).
The above in vitro data were then corroborated with experiments in vivo. In two different models, SCID mice were engrafted either i.p. or subcutaneously with 3 Â 10 6 Daudi cells labeled with FFLuc. After 7 days, these mice were treated with two weekly infusions i.p. (for mice engrafted with i.p. tumor) or i.v (for mice engrafted with subcutaneous tumor) of control NT, CAR.19 þ or iC9/CAR.19/IL-15 þ T cells (10 Â 10 6 ). Tumor growth was monitored by measuring changes in tumor bioluminescence over time. As shown in Figures 5a and b , the tumor bioluminescence of mice engrafted i.p. with Daudi cells rapidly increased in recipients of control NT T cells (rising from 1.8 Â 10 8 ± 4 Â 10 7 to 16 Â 10 8 ± 2.6 Â 10 8 by day 38). CAR.19 þ T cells transiently controlled tumor growth (from 1.9 Â 10 8 ± 3 Â 10 7 to 9.3 Â 10 8 ± 1.6 Â 10 8 by day 38), whereas iC9/CAR.19/IL-15 þ T cells significantly controlled tumor expansion so that signal rose from 1.6 Â 10 8 ± 3 Â 10 7 to only 1.7 Â 10 8 ±5 Â 10 8 by day 38 (P ¼ 0.001 when compared with mice receiving CAR.19 þ T cells). Similarly, the tumor bioluminescence of mice engrafted subcutaneously with Daudi cells rapidly increased in mice receiving control NT T cells (from iC9/CAR.19/IL-15 þ T cells are eliminated after activation of the suicide gene by exposure to the small-molecule CID Because the production of an autocrine growth factor raises concerns about autonomous, uncontrolled T-cell growth, we incorporated in our construct a suicide gene based on the inducible caspase-9 gene. 26, 27 As shown in Figure 6a , the addition of 50 nM CID to cultures of iC9/CAR.19/IL-15 þ T cells induced apoptosis/necrosis of 495% of transgenic cells within 24 h, as assessed by annexin-V-7AAD staining. 27 The suicide gene was also effective in vivo. Mice were engrafted i.v. with Raji tumor cells and then infused with eGFP-FFLuc labeled iC9/CAR.19/IL-15 þ T cells. These cells localized and expanded at the tumor site by day 14 after infusion as assessed by bioluminescence measurement (Figure 6b) . T-cell bioluminescence drastically reduced (from 1.2 Â 10 6 ± 7.7 Â 101 5 to 1.3 Â 10 5 ±3 Â 10 4 ) after administration of the CID, consistent with a significant elimination of the transgenic cells. 27 
IL-15 expression improves proliferation and antitumor effects of CAR.19 þ T cells generated from B-CLL samples
Finally, we validated the efficacy of the combination of CAR.19, IL-15 and the suicide gene in cells obtained from subjects with B-CLL. As shown in Figure 7a , the expansion of T cells isolated from B-CLL patients was enhanced after transduction with the iC9/CAR.19/IL-15 vector and stimulation with autologous B-CLL cells (E:T ratio of 1:1) compared with CAR.19 þ T cells (228 Â 10 6 ±315 Â 10 6 total cells vs 7 Â 10 6 ±2.7 Â 10 6 total cells, respectively). Their expansion remained fully antigen dependent as we observed for T-cell lines generated from healthy donors (Figure 7b) T cells coexpressing CD19-specific CAR and IL-15 V Hoyos et al also released both IL-15 (103±39 pg/ml/10 6 cells) and IL-2 (62 ± 24 pg/ml/10 6 cells) in response to autologous B-CLL cells, whereas CAR.19 þ T cells produced only IL-2 (65±33 pg/ml/10 6 cells; Figure 7c ). Expansion of patients' T cells was mainly driven by the antiapoptotic effect of IL-15 upon antigen stimulation (Figure 7d ). We also confirmed that iC9/CAR.19/ IL-15 þ patient T cells retained enhanced antitumor activity against autologous B-CLL after long-term culture and repeated exposure to autologous tumor cells, whereas CAR.19 þ patient T cells did not (Figure 7e ).
Discussion
We have forced expression of IL-15 in T cells redirected with a CAR that specifically targets the CD19 antigen, and shown that these engineered T cells had superior survival, expansion and antitumor activity in vivo when compared with redirected T cells that only receive CD28 costimulation through the CAR but lack IL-15 production. Importantly, the incorporation of an inducible suicide gene and its pharmacologic activation efficiently eliminated these gene-modified T cells, further increasing the safety of the proposed approach.
In vivo persistence and expansion of adoptively transferred tumor-specific T cells is crucial to obtain sustained clinical responses. 32 This is particularly important for T cells engrafted with CARs that lack costimulatory endodomains, as they do not release helper cytokines upon engagement with the antigen expressed by tumor cells. 10, 14, 15, 33, 34 In addition, they cannot receive appropriate activation by professional antigen-presenting cells in secondary lymphoid organs, as the native abT-cell receptors of these redirected T cells are not generally specific for latent antigens consistently processed and presented by the host antigen-presenting cells. 4, 13 The incorporation of the T cells coexpressing CD19-specific CAR and IL-15 V Hoyos et al CD28 costimulatory signaling domain as part of the CAR itself 10, 14, 15, 33 can enhance activation and proliferation of these cells secondary to IL-2 secretion, even without cross-presentation by antigen-presenting cells. 10, 15 However, the overall persistence and antitumor effects of such CAR.19-redirectd T cells still remain limited. 10, 14, 19 Alternative costimulatory endodomains may be superior to CD28, and incorporation of 4-1BB endodomain, for example, 16, 35 or a combination of both CD28 and 4-1BB, has been reported to increase the persistence and antitumor efficacy over CD28-containing CARs. [18] [19] [20] [21] Nevertheless, we reasoned that the ectopic production of IL-15 by CAR-modified T cells may represent a valid addition to the incorporation of costimulatory endodomains within the CAR construct as the benefits would occur through different pathways and mechanisms, because neither CD28 nor 4-1BB costimulation lead to the production of IL-15, a cytokine that potently enhances the antitumor activity of effector T cells in vitro and in vivo. 8, 36, 37 Our approach ensures that CARmodified T cells receive both IL-2 and IL-15 stimulation after chimeric receptor engagement in the tumor microenvironment.
We have accommodated the IL-15 gene in a single retrovirus vector in combination with the CAR.19 encoding the CD28 endodomain and an inducible suicide gene without significantly affecting CAR.19 expression, an essential requirement if tumor specificity is to be maintained. Minimal cytokine is produced when the T cells are unstimulated, but the amount significantly increases after stimulation with tumor cells, and production is maintained by the T cells after more than 4 weeks of culture. This transgenic IL-15 is biologically functional, as iC9/CAR.19/IL-15 þ T cells have superior expansion after antigen stimulation than control CAR.19 þ T cells. These benefits are largely attributable to the reduced susceptibility of iC9/CAR.19/IL-15 þ T cells to cell death induced upon antigen stimulation, likely because these cells have higher expression of the antiapoptotic gene Bcl-2 38 when compared with control CAR.19 þ T cells. Importantly, our in vitro experiments show that iC9/CAR.19/IL-15 þ T cells retain enhanced antitumor activity when they are 'chronically' exposed to tumor cells. This effect may be determined by an increased protection of iC9/CAR.19/IL-15 þ T cells from functional exhaustion, as indicated by a lower expression of PD-1 upon antigen stimulation than CAR.19 þ T cells, as PD-1 has been recognized as a marker of exhausted T cells in chronic infections such as human immunodeficiency virus, 31 hepatitis C 39 and tumorinfiltrating T lymphocytes. [40] [41] [42] [43] We do not yet know the transcriptional or post-transcriptional mechanisms that reduce expression of PD-1 in iC9/CAR.19/IL-15 þ T cells after repeated antigen stimulation. Nonetheless, our observation may have clinical implications as CAR-modified T cells that target selfantigens, such as CD19, will inevitably be exposed to a large number of target cells in vivo, and PD-1 ligands may be expressed by either the tumor cell itself 40, 42, 43 or by tumorassociated dendritic cells. 44 The improved antitumor effects observed in vitro were matched by superior in vivo activity, and iC9/CAR.19/IL-15 þ T cells retained their tumor homing, expanded at tumor sites and had enhanced antitumor activity compared with control CAR.19 þ T cells.
Recently, intermittent systemic administration of recombinant IL-15 has been shown to induce expansion of memory CD4 þ and CD8 þ T cells in nonhuman primates. 45 Administration of IL-15 will soon be tested in patients to support the expansion of adoptively transferred tumor-specific T cells. We suggest that our proposed approach may remain advantageous as it delivers the cytokine directly to T cells at the tumor site, avoiding the toxicities that may be observed in patients receiving systemic administration of recombinant cytokines, especially when the cytokine is used at high doses. 46 Our approach will also remain valuable for adoptive transfer of tumor-specific T lymphocytes in lymphodepleted patients 47 as it ensures long-term availability of IL-15 for tumor-specific T cells to overcome the antiproliferative effect of transforming growth factor-b 48 and regulatory T cells 49 (and manuscript in preparation) within the tumor microenvironment.
Because IL-15 production by gene-modified T cells occurs predominantly after they engage tumor cells through their CARs, the risks of autonomous growth should remain small. Nonetheless, given the concerns regarding retroviral-associated oncogenesis, 25 and the potential side effects reported after T-cell therapy with CAR-modified T cells, 11, 50 we incorporated a suicide gene based on the inducible caspase-9 molecule within our construct. We showed that the activation of this suicide gene rapidly induces apoptosis of IL-15-producing T cells both in vitro and in vivo. Our previous observation that the small fraction of cells (o10%) that seem to escape apoptosis/necrosis shortly after exposure to the dimerizer drug do not express detectable levels of any transgene, including cytokine, 27 nor proliferate after antigen stimulation, 27 may further increase the safety of the proposed approach. This suicide gene is already under evaluation in a phase I clinical trial in which patients undergoing haploidentical transplant receive donor-derived T cells gene modified with the inducible caspase-9 gene. 51 In conclusion, we show that transgenic expression of IL-15 improves survival, expansion and antitumor effects of CD19specific redirected T cells. The incorporation of an effective suicide gene should further assure the safety of the approach and increase its potential clinical applicability.
